(MENAFN- GlobeNewsWire - Nasdaq) The uveitis market report for the 7MM (US, 5EU, Japan) projects a rise in diagnosed cases and a market growth from $522.5M in 2023 to $1.5B by 2033, at a 10.9% CAGR. It covers epidemiology, current treatments, unmet needs, and profiles six late-stage pipeline agents. Key insights for strategic and competitive advantage included.

Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The "Uveitis: Opportunity Assessment and Forecast - Update" report has been added to ResearchAndMarkets.com's offering.
The uveitis market in the 7MM was valued at $522.5 million in 2023. The market is projected to grow at a CAGR of 10.9%, reaching $1.5 billion by 2033.

This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033. There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies. Significant clinical unmet needs remain in the uveitis market. The late-stage uveitis pipeline consists of six agents.
Scope

• Overview of uveitis, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized uveitis therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2023 and forecast for 10 years to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the uveitis therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for uveitis treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM uveitis therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the uveitis therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the uveitis therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:
1. Preface
1.1. Contents
1.2. Abbreviations
1.3. Summary of Updates
1.4. Related Reports
2. Executive Summary
3. Disease Overview
3.1. Overview of Uveitis
3.2. Uveitis SWOT Analysis
3.3. Progression of Uveitis
3.4. Diagnosis and Classification of Uveitis
4. Epidemiology
4.1. Diagnosed Incident Cases of Uveitis
4.2. Diagnosed Prevalent Cases of Uveitis
4.3. Age-Specific Trends in Diagnosed Prevalent Cases of Uveitis
4.4. Sex-Specific Diagnosed Prevalent Cases of Uveitis
4.5. Diagnosed Prevalent Cases of Uveitis by Etiology, Anatomical Site of Inflammation, and Severity
4.6. Sources and Methodology for Diagnosed Incident Cases of Uveitis
4.7. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis
4.8. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation
4.9. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Etiology
4.10. Sources and Methodology for Diagnosed Prevalent Cases of Uveitis by Severity
4.11. Sources and Methodology - Diagnosed Incident and Prevalent Cases of Uveitis
4.12. Sources and Methodology - Diagnosed Prevalent Cases of Uveitis by Anatomical Site
5. Current Treatment Options
5.1. Treatment Paradigm
5.2. Current Treatment Options
5.3. Current Treatment Options: Key Opinion Leader Perspective
5.4. Product Profile: Corticosteroid Eye Drops
5.5. Product Profile: Ocular Steroid Injections
5.6. Product Profile: Intraocular Corticosteroid Implants
5.7. Product Profile: Systemic Corticosteroids
5.8. Product Profile: Mydriatic Agents
5.9. Product Profile: Antimetabolites
5.10. Product Profile: Alkylating Agents
5.11. Product Profile: Calcineurin Inhibitors
5.12. Product Profile: Monoclonal Antibodies
5.13. Product Profile: Adrenocorticotropic Hormone Receptor Agonists
6. Unmet Needs and Opportunities
6.1. Unmet Needs in Uveitis
6.2. Improving Safety and Side-Effect Profile
6.3. Longer-Acting Therapy/Less Frequent Dosing
6.4. Drugs with Other Mechanisms of Action
6.5. Greater Awareness and Education of Physicians/Healthcare Providers
7. R&D Strategies
7.1. Trends in Clinical Trial Design for Uveitis
7.2. Trends in Deal-Making in Uveitis
8. Pipeline Assessment
8.1. Uveitis Pipeline Overview
8.2. Late-Stage Pipeline Agents for Uveitis
8.3. Product Profile: OCS-02
8.4. Product Profile: TRS-01
8.5. Product Profile: brepocitinib tosylate
8.6. Product Profile: Baricitinib
8.7. Product Profile: KIO-104
8.8. Product Profile: EBI-031
8.9. Uveitis Clinical Trials (Phase II/III) Overview
9. Market Outlook
9.1. Uveitis Market Outlook
9.2. Uveitis Market Forecast
9.3. Market Drivers and Barriers
10. Appendix

Companies Featured

• Apothecon
• Allergan
• Pfizer
• Novartis
• Baxter Healthcare
• AbbVie
• Bausch & Lomb
• EyePoint Pharmaceuticals
• Astellas
• Janssen
• Gennentech
• Oculis Holding AG
• Tarsier Pharma Ltd
• Priovant Therapeutics Inc
• Eli Lilly
• Kiora Pharmaceuticals Inc
• F. Hoffman-La Roche

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN03092025004107003653ID1110012793